zanidatamab + cisplatin + gemcitabine

Zanidatamab + cisplatin + gemcitabine is a combination therapy used for the treatment of HER2-positive cancers, primarily advanced or metastatic gastroesophageal adenocarcinoma and biliary tract cancer. - **Zanidatamab** is a humanized, bispecific IgG1-like monoclonal antibody that targets two distinct non-overlapping epitopes (extracellular domains 2 and 4) of the HER2 protein on cancer cells, leading to HER2 clustering, internalization, downregulation, and multiple mechanisms of cytotoxicity, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP), and signal blockade of HER2-driven growth pathways[1][3][5][7]. - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, thereby inhibiting DNA synthesis and function, leading to apoptosis of rapidly dividing tumor cells. - **Gemcitabine** is a nucleoside analog and antimetabolite that is incorporated into DNA during replication, resulting in termination of DNA chain elongation and apoptosis of dividing cells. This combination is under investigation and in late-stage clinical trials as first-line therapy for advanced HER2-positive cancers, where it is compared to standard of care regimens[4].